{
    "clinical_study": {
        "@rank": "85598", 
        "arm_group": {
            "arm_group_label": "Oncology Institute, Meir Medical Center", 
            "description": "Metastatic cancer patients treated with docetaxel at the Oncology Institute, Meir Medical Center"
        }, 
        "brief_summary": {
            "textblock": "Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including\n      lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer.\n\n      One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein.\n\n      Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated\n      with the outcome of docetaxel based therapy in cancer patients.\n\n      The investigators aim to prospectively study the association between the plasma level of\n      alpha 1 acid glycoprotein and the outcome of docetaxel based therapy in cancer patients."
        }, 
        "brief_title": "The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Metastatic Lung Cancer", 
            "Metastatic Breast Cancer", 
            "Metastatic Gastric Cancer", 
            "Metastatic Prostate Cancer", 
            "Metastatic Bladder Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Urinary Bladder Neoplasms", 
                "Breast Neoplasms", 
                "Lung Neoplasms", 
                "Stomach Neoplasms", 
                "Neoplasm Metastasis", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including\n      non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder\n      cancer.\n\n      One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein\n\n      Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated\n      with the outcome of docetaxel based therapy in non small cell lung cancer patients.\n\n      The investigators aim to prospectively study the association between the baseline  plasma\n      level of alpha 1 acid glycoprotein (measured on the first day of the first cycle of\n      docetaxel) and the outcome (response rete, progression free survival, overall survival) of\n      docetaxel based therapy in patients with metastatic non small cell lung cancer, breast\n      cancer, stomach cancer, prostate cancer, and bladder cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  patients with metastatic cancer from lung, breast, gastric, prostate, and bladder\n             origin\n\n          -  patients must be treated with docetaxel based chemotherapy\n\n          -  patients must sign an informed consent form\n\n        Exclusion Criteria\n\n          -  patients with metastatic cancer other than lung, breast, gastric, prostate, and\n             bladder origin\n\n          -  patients treated with chemotherapy other than docetaxel\n\n          -  patients that did not sign an informed consent form"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with Metastatic cancer from lung, breast, gastric, prostate, and bladder origin,\n        treated with docetaxel based chemotherapy"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814150", 
            "org_study_id": "A1AGP1234"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Krestin", 
                "Docetaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Docetaxel", 
            "Alpha 1 Acid Glycoprotein", 
            "Outcome"
        ], 
        "lastchanged_date": "March 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kfar-Saba", 
                    "country": "Israel"
                }, 
                "name": "Institute of Oncology, Meir Medical Center"
            }, 
            "investigator": {
                "last_name": "Daniel Keizman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Association Between Alpha 1 Acid Glycoprotein Level and Outcome of Patients With Metastatic Cancer Treated With Docetaxel Based Chemotherapy", 
        "overall_contact": {
            "email": "danielkeizman@gmail.com", 
            "last_name": "Daniel Keizman, MD", 
            "phone": "97297471408"
        }, 
        "overall_official": {
            "affiliation": "Meir Medical Center", 
            "last_name": "Daniel Keizman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The association between the baseline plasma level of alpha 1 acid glycoprotein and progression free survival of docetaxel based therapy in patients with metastatic non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer", 
            "measure": "The association between the baseline plasma level of alpha 1 acid glycoprotein and progression free survival of docetaxel based therapy in patients with metastatic cancer", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814150"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Meir Medical Center", 
            "investigator_full_name": "Gottfried Maya", 
            "investigator_title": "Head, Institution of Oncology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "The association between the baseline plasma level of alpha 1 acid glycoprotein and the response rate and overall survival of docetaxel based therapy in patients with metastatic non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer", 
            "measure": "The association between the baseline plasma level of alpha 1 acid glycoprotein and the response rate and overall survival of docetaxel based therapy in patients with metastatic cancer", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "Meir Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gottfried Maya", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2013"
    }
}